Marks Group Wealth Management Inc Purchases Shares of 10,331 Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

Marks Group Wealth Management Inc bought a new stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 10,331 shares of the company's stock, valued at approximately $373,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new position in Zai Lab during the 4th quarter valued at about $1,032,000. Oppenheimer Asset Management Inc. purchased a new position in Zai Lab during the 1st quarter valued at about $603,000. BNP Paribas Financial Markets increased its holdings in Zai Lab by 1,439.8% during the 4th quarter. BNP Paribas Financial Markets now owns 19,755 shares of the company's stock valued at $517,000 after acquiring an additional 18,472 shares in the last quarter. FMR LLC grew its holdings in shares of Zai Lab by 749.1% during the fourth quarter. FMR LLC now owns 5,475,505 shares of the company's stock worth $143,403,000 after buying an additional 4,830,646 shares in the last quarter. Finally, US Bancorp DE grew its holdings in shares of Zai Lab by 1,671.9% during the fourth quarter. US Bancorp DE now owns 5,865 shares of the company's stock worth $154,000 after buying an additional 5,534 shares in the last quarter. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ZLAB. Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the stock an "outperform" rating in a report on Monday, June 30th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th. Finally, Wall Street Zen downgraded shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $54.28.

Zai Lab Stock Performance

Zai Lab stock traded up $0.54 during trading on Thursday, reaching $36.01. The company had a trading volume of 1,315,363 shares, compared to its average volume of 917,152. Zai Lab Limited Unsponsored ADR has a 12-month low of $16.01 and a 12-month high of $44.34. The stock's 50 day moving average price is $34.55 and its two-hundred day moving average price is $31.89. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of -14.46 and a beta of 0.99.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.05. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. The firm had revenue of $106.49 million during the quarter, compared to the consensus estimate of $118.40 million. As a group, research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Insider Activity at Zai Lab

In related news, CEO Ying Du sold 7,072 shares of the business's stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $35.23, for a total value of $249,146.56. Following the completion of the sale, the chief executive officer directly owned 536,962 shares in the company, valued at approximately $18,917,171.26. The trade was a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William Lis sold 13,814 shares of the business's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $35.67, for a total transaction of $492,745.38. Following the completion of the sale, the director owned 35,106 shares of the company's stock, valued at approximately $1,252,231.02. The trade was a 28.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 160,155 shares of company stock worth $4,959,535. 4.96% of the stock is owned by company insiders.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.